Clinical effectiveness of rehabilitation in ambulatory care for patients with persisting symptoms after COVID-19: a systematic review.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
21 Jun 2023
Historique:
received: 18 01 2023
accepted: 05 06 2023
medline: 23 6 2023
pubmed: 22 6 2023
entrez: 21 6 2023
Statut: epublish

Résumé

Lingering symptoms after acute COVID-19 present a major challenge to ambulatory care services. Since there are reservations regarding their optimal management, we aimed to collate all available evidence on the effects of rehabilitation treatments applicable in ambulatory care for these patients. On 9 May 2022, we systematically searched articles in COVID-19 collections, Embase, MEDLINE, Cochrane Library, Web of Science, CINAHL, PsycArticles, PEDro, and EuropePMC. References were eligible if they reported on the clinical effectiveness of a rehabilitation therapy applicable in ambulatory care for adult patients with persisting symptoms continuing 4 weeks after the onset of COVID-19. The quality of the studies was evaluated using the CASP cohort study checklist and the Cochrane Risk of Bias Assessment Tool. Summary of Findings tables were constructed and the certainty of evidence was assessed using the GRADE framework. We included 38 studies comprising 2,790 participants. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, but the evidence is very weak (based on 6 RCTs and 12 cohort studies). The evidence underpinning the effect of nutritional supplements on fatigue, dyspnoea, muscle pain, sensory function, psychological well-being, quality of life, and functional capacity is very poor (based on 4 RCTs). Also, the evidence-base is very weak about the effect of olfactory training on sensory function and quality of life (based on 4 RCTs and 3 cohort studies). Multidisciplinary treatment may have beneficial effects on fatigue, dyspnoea, physical capacity, pulmonary function, quality of life, return to daily life activities, and functional capacity, but the evidence is very weak (based on 5 cohort studies). The certainty of evidence is very low due to study limitations, inconsistency, indirectness, and imprecision. Physical training, breathing exercises, olfactory training and multidisciplinary treatment can be effective rehabilitation therapies for patients with persisting symptoms after COVID-19, still with high uncertainty regarding these effects. These findings can guide ambulatory care practitioners to treat these patients and should be incorporated in clinical practice guidelines. High-quality studies are needed to confirm our hypotheses and should report on adverse events.

Sections du résumé

BACKGROUND BACKGROUND
Lingering symptoms after acute COVID-19 present a major challenge to ambulatory care services. Since there are reservations regarding their optimal management, we aimed to collate all available evidence on the effects of rehabilitation treatments applicable in ambulatory care for these patients.
METHODS METHODS
On 9 May 2022, we systematically searched articles in COVID-19 collections, Embase, MEDLINE, Cochrane Library, Web of Science, CINAHL, PsycArticles, PEDro, and EuropePMC. References were eligible if they reported on the clinical effectiveness of a rehabilitation therapy applicable in ambulatory care for adult patients with persisting symptoms continuing 4 weeks after the onset of COVID-19. The quality of the studies was evaluated using the CASP cohort study checklist and the Cochrane Risk of Bias Assessment Tool. Summary of Findings tables were constructed and the certainty of evidence was assessed using the GRADE framework.
RESULTS RESULTS
We included 38 studies comprising 2,790 participants. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, but the evidence is very weak (based on 6 RCTs and 12 cohort studies). The evidence underpinning the effect of nutritional supplements on fatigue, dyspnoea, muscle pain, sensory function, psychological well-being, quality of life, and functional capacity is very poor (based on 4 RCTs). Also, the evidence-base is very weak about the effect of olfactory training on sensory function and quality of life (based on 4 RCTs and 3 cohort studies). Multidisciplinary treatment may have beneficial effects on fatigue, dyspnoea, physical capacity, pulmonary function, quality of life, return to daily life activities, and functional capacity, but the evidence is very weak (based on 5 cohort studies). The certainty of evidence is very low due to study limitations, inconsistency, indirectness, and imprecision.
CONCLUSIONS CONCLUSIONS
Physical training, breathing exercises, olfactory training and multidisciplinary treatment can be effective rehabilitation therapies for patients with persisting symptoms after COVID-19, still with high uncertainty regarding these effects. These findings can guide ambulatory care practitioners to treat these patients and should be incorporated in clinical practice guidelines. High-quality studies are needed to confirm our hypotheses and should report on adverse events.

Identifiants

pubmed: 37344767
doi: 10.1186/s12879-023-08374-x
pii: 10.1186/s12879-023-08374-x
pmc: PMC10283248
doi:

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

419

Subventions

Organisme : Belgische Federale Overheidsdiensten
ID : QPG-3D1907-VERBAKEL/TROOSTERS/GOSSELINK-FOD-COVID
Organisme : Belgische Federale Overheidsdiensten
ID : 2021-2022

Informations de copyright

© 2023. The Author(s).

Références

EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Occup Ther Int. 2022 Apr 14;2022:4590154
pubmed: 35521629
J Clin Med. 2021 Sep 27;10(19):
pubmed: 34640447
Respir Med. 2021 Nov-Dec;189:106648
pubmed: 34689061
Int J Environ Res Public Health. 2021 Aug 26;18(17):
pubmed: 34501596
Clin Med (Lond). 2021 Nov;21(6):e629-e632
pubmed: 34862223
Complement Ther Med. 2022 Aug;67:102823
pubmed: 35341944
J Med Virol. 2023 Jan;95(1):e28373
pubmed: 36461167
EClinicalMedicine. 2022 Dec 01;55:101762
pubmed: 36474804
J Affect Disord. 2021 Oct 1;293:141-147
pubmed: 34186232
Disabil Rehabil. 2022 Nov;44(22):6833-6840
pubmed: 34559592
Chron Respir Dis. 2021 Jan-Dec;18:14799731211015691
pubmed: 33957805
Neurologia. 2021 Sep;36(7):565-566
pubmed: 34629604
Am J Otolaryngol. 2021 Mar-Apr;42(2):102884
pubmed: 33429174
Phys Ther. 2022 Apr 1;102(4):
pubmed: 35079817
Int J Environ Res Public Health. 2021 Apr 09;18(8):
pubmed: 33918887
Vaccines (Basel). 2021 May 12;9(5):
pubmed: 34066007
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
J Med Internet Res. 2021 May 27;23(5):e29583
pubmed: 34003765
Int Forum Allergy Rhinol. 2022 Dec;12(12):1570-1574
pubmed: 35758174
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
PM R. 2021 Jun;13(6):609-617
pubmed: 33599057
Curr Neuropharmacol. 2022;20(10):2001-2012
pubmed: 35450527
J R Soc Med. 2021 Sep;114(9):428-442
pubmed: 34265229
Complement Ther Clin Pract. 2020 May;39:101166
pubmed: 32379637
Lancet Respir Med. 2022 Sep;10(9):851-862
pubmed: 35489367
Front Med (Lausanne). 2022 Feb 21;9:837420
pubmed: 35265644
Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4156-4162
pubmed: 34156697
PLoS One. 2021 Jul 12;16(7):e0254523
pubmed: 34252157
Can J Respir Ther. 2022 Mar 09;58:20-27
pubmed: 35359819
Bull World Health Organ. 2022 Nov 1;100(11):676-688
pubmed: 36324552
ERJ Open Res. 2021 May 31;7(2):
pubmed: 34095290
Am J Rhinol Allergy. 2022 Nov;36(6):780-787
pubmed: 35866202
Respir Med. 2021 Jul;183:106438
pubmed: 33964817
Scand J Med Sci Sports. 2022 Dec;32(12):1791-1801
pubmed: 36111386
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Eur Arch Otorhinolaryngol. 2021 Aug;278(8):3113-3117
pubmed: 33423106
Medicines (Basel). 2021 Aug 30;8(9):
pubmed: 34564089
Int J Environ Res Public Health. 2022 Apr 24;19(9):
pubmed: 35564579
Cardiovasc Endocrinol Metab. 2022 Apr 12;11(2):e0261
pubmed: 35441129
Respiration. 2022;101(6):593-601
pubmed: 35203084
Physiotherapy. 2021 Jun;111:4-22
pubmed: 33637294
Clin Rehabil. 2022 Jan;36(1):59-68
pubmed: 34344230
Eur J Prev Cardiol. 2022 May 25;29(7):e258-e260
pubmed: 35078233
Eur J Phys Rehabil Med. 2022 Apr;58(2):328-331
pubmed: 35244366
Thorax. 2022 Jul;77(7):697-706
pubmed: 34312316
J Clin Med. 2022 Jun 08;11(12):
pubmed: 35743346
J Rehabil Med. 2022 Jan 03;54:jrm00242
pubmed: 34633050
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Ann Phys Rehabil Med. 2023 Feb;66(1):101709
pubmed: 36191860
Lancet Respir Med. 2021 Nov;9(11):1275-1287
pubmed: 34627560
J Pers Med. 2021 Aug 18;11(8):
pubmed: 34442450
BMJ Open Respir Res. 2021 Sep;8(1):
pubmed: 34489236

Auteurs

Hannelore Dillen (H)

EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 7 Kapucijnenvoer, 3000, Leuven, Belgium. hannelore.dillen@kuleuven.be.
Academic Centre for General Practice, Department of Public Health and Primary Care, KU Leuven, 7 Kapucijnenvoer, 3000, Leuven, Belgium. hannelore.dillen@kuleuven.be.

Geertruida Bekkering (G)

Academic Centre for General Practice, Department of Public Health and Primary Care, KU Leuven, 7 Kapucijnenvoer, 3000, Leuven, Belgium.
Centre for Evidence-Based Medicine, 7 Kapucijnenvoer, 3000, Leuven, Belgium.
Cochrane Belgium, 7 Kapucijnenvoer, 3000, Leuven, Belgium.

Sofie Gijsbers (S)

, post-COVID community, Belgium.

Yannick Vande Weygaerde (Y)

Department of Respiratory Medicine, Ghent University Hospital, 10 Corneel Heymanslaan, 9000, Ghent, Belgium.

Maarten Van Herck (M)

REVAL-Rehabilitation Research Center, Biomedical Research Institute (BIOMED), Faculty of Rehabilitation Sciences, Hasselt University, Agoralaan Building A, 3590, Diepenbeek, Belgium.
Department of Research and Development, Ciro, 1 Hornerheide, Horn, 6085 NM, The Netherlands.
Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, 25 P. Debyelaan, Maastricht, 6229 HX, The Netherlands.

Sarah Haesevoets (S)

REVAL-Rehabilitation Research Center, Biomedical Research Institute (BIOMED), Faculty of Rehabilitation Sciences, Hasselt University, Agoralaan Building A, 3590, Diepenbeek, Belgium.

David A G Bos (DAG)

EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 7 Kapucijnenvoer, 3000, Leuven, Belgium.
Academic Centre for General Practice, Department of Public Health and Primary Care, KU Leuven, 7 Kapucijnenvoer, 3000, Leuven, Belgium.

Ann Li (A)

, post-COVID community, Belgium.

Wim Janssens (W)

Department of Respiratory Diseases, KU Leuven University Hospitals Leuven, 49 Herestraat, 3000, Leuven, Belgium.

Rik Gosselink (R)

Department of Rehabilitation Sciences, Research Group for Rehabilitation in Internal Disorders, KU Leuven, 101 Tervuursevest, 3001, Leuven, Belgium.

Thierry Troosters (T)

Department of Rehabilitation Sciences, Research Group for Rehabilitation in Internal Disorders, KU Leuven, 101 Tervuursevest, 3001, Leuven, Belgium.

Jan Y Verbakel (JY)

EPI-Centre, Department of Public Health and Primary Care, KU Leuven, 7 Kapucijnenvoer, 3000, Leuven, Belgium.
Academic Centre for General Practice, Department of Public Health and Primary Care, KU Leuven, 7 Kapucijnenvoer, 3000, Leuven, Belgium.
NIHR Community Healthcare Medtech and IVD Cooperative, Nuffield Department of Primary Care Health Sciences, University of Oxford, Woodstock Road, Oxford, OX2 6GG, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH